6.4.2 Male sex hormones and antagonists

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

BNF Category

74 library items in 6.4.2 Male sex hormones and antagonists

Filter results by:

Date Published

NeLM Area

News
Other Library Updates
Health In Focus
Evidence
Medicines A-Z
Communities
Formularies

Results filtered by:

Category

6: Endocrine system (remove) , 6.4 Sex hormones (remove) , 6.4.2 Male sex hormones and antagonists (remove)

Sort by: Display summary:

Results 1 - 10 of 74

Result page:
Previous
|
1
2
3
4
5
6
7
8
|
Next

1.

Sexual side effect warnings in US finasteride labels to be updated

Source: Reuters Health, Medscape, FDA,
Date published: 13/04/2012

Category:

6.4.2 Male sex hormones and antagonists | 13.9 Shampoos and other preparations for scalp and hair conditions | Adverse Drug Reactions | Benign prostatic hypertrophy | Food &Drug Administration (FDA)

NeLM Area:

News

Reuters report (subscribers only)

Medscape report

Link to FDA Q&A document
2.

Editorial - Cardiovascular risk in androgen suppression

Source: Heart,
Date published: 08/02/2012

Category:

6.4.2 Male sex hormones and antagonists | Cancer: prostate

NeLM Area:

News

Abstract
3.

Dutasteride useful in addition to active surveillance for localised prostate cancer?

Source: Lancet,
Date published: 24/01/2012

Category:

6.4.2 Male sex hormones and antagonists | Cancer: prostate

NeLM Area:

News

Link (abstract)

Comment
4.

Systematic review: Use of prostate specific antigen values as surrogate endpoints to determine duration of androgen deprivation therapy

Source: Lancet Oncology,
Date published: 24/11/2011

Category:

6.4.2 Male sex hormones and antagonists | Cancer: prostate

NeLM Area:

News

Abstract

Comment
5.

Avodart 0.5mg soft capsules (Dutasteride)- Revised SPC

Source: eMC (electronic Medicines Compendium),
Date published: 20/10/2011

Category:

6.4.2 Male sex hormones and antagonists

NeLM Area:

Other Library Updates > SPC Changes

SPC
6.

The Enlarged Prostate International Comparator Study (EPICS) comparison of dutasteride and finasteride for benign prostatic hyperplasia shows no difference in outcomes

Source: British Journal of Urology International ,
Date published: 21/06/2011

Category:

6.4.2 Male sex hormones and antagonists | Cancer: prostate

NeLM Area:

News

Abstract
7.

Perspective: FDA rejects finasteride and dutasteride for prostate cancer prevention

Source: New England Journal of Medicine,
Date published: 16/06/2011

Category:

6.4.2 Male sex hormones and antagonists | Adverse Drug Reactions | Cancer: prostate | Food &Drug Administration (FDA)

NeLM Area:

News

Full text of article (available freely at time of posting)
8.

FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer

Source: FDA,
Date published: 10/06/2011

Category:

6.4.2 Male sex hormones and antagonists | Adverse Drug Reactions | Cancer: prostate | Food &Drug Administration (FDA)

NeLM Area:

News

FDA MedWatch press release

FDA press release
9.

Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis

Source: DARE,
Date published: 05/04/2011

Category:

6.4.2 Male sex hormones and antagonists | 7.4.5 Drugs for erectile dysfunction | Erectile dysfunction

NeLM Area:

Evidence > Drug Class Focused Reviews

DARE abstract
10.

GSK withdraws licensing applications for dutasteride (Avodart) in prostate cancer

Source: PharmaTimes,
Date published: 25/03/2011

Category:

6.4.2 Male sex hormones and antagonists | Adverse Drug Reactions | Cancer: prostate | Licence extension

NeLM Area:

News

Link- registration required

Results 1 - 10 of 74

Result page:
Previous
|
1
2
3
4
5
6
7
8
|
Next